ANDA 204560, held by Onesource Specialty. Ganciclovir Sodium.
As of Nov 16, 2026, ANDA 204560 (Ganciclovir Sodium), held by Onesource Specialty, was first approved by FDA on Nov 17, 2017, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ganciclovir SodiumEQ 500MG BASE/VIAL · injectable;injection | Ganciclovir Sodium | Discontinued |
| May 18, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 17, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters